Devyser announces study publication demonstrating dd-cfDNA detection in dual donor kidney transplant patients
Devyser Diagnostics AB announces today an article titled “Detection of donor-derived cell-free DNA...
We are excited to announce that we will be attending the cfDNA2023 conference. The meeting promises to provide an excellent overview of the field as presented by key experts and give us the opportunity to discuss scientific and clinical topics with peers from the field. We look forward to learning from and contributing to the conversation at cfDNA2023.
“During early pregnancy, 3-6% of cell-free DNA in the plasma of pregnant women is of fetal origin.”
Dr. Agneta Wikman, M.D., Ph.D, Karolinska University Hospital, Stockholm, Sweden
Choosing and implementing the best screening method for non-invasive fetal-RHD testing. Learn from clinical experts about the shift in today’s screening method for non-invasive fetal-RHD testing. Dr Wikman is a professor and specialist in Transfusion Medicine and Laboratory Medicine.
News | October 29, 2024
Devyser seeks to secure FDA approval for NGS test for kidney transplant monitoringNews | October 28, 2024
Devyser Compact achieves Class III approval in ChinaDevyser Diagnostics AB announces today an article titled “Detection of donor-derived cell-free DNA...
Read More
Read More
Devyser’s novel test for detecting donor-derived cell-free DNA in blood samples from...
Read More
A better patient care is the final objective for Dr. Helena Devos and the team at Sint Jan’s...
Read More